Steatohepatitis Stocks List

Steatohepatitis Stocks Recent News

Date Stock Title
Nov 21 GNFT Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions
Nov 20 IVA Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024
Nov 20 IVA Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
Nov 20 BLTE Belite Bio: Interesting Science, But Quite A Few Worries
Nov 19 ALGS Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
Nov 18 PLRX Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
Nov 18 AKRO Akero a new buy at Citi on liver disease asset
Nov 18 GALT Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
Nov 18 SGMT Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Nov 18 SGMT Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them.
Nov 18 IVA The first MASH drug could open the door for others — including GLP-1s
Nov 15 IVA Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Nov 15 AKRO Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
Nov 15 ETNB 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
Nov 14 SGMT Sagimet: More Than Just A MASH Drug Development Biotech
Nov 14 SGMT Sagimet Biosciences GAAP EPS of -$0.45
Nov 14 GALT Galectin Therapeutics GAAP EPS of -$0.18
Steatohepatitis

Steatohepatitis is a type of fatty liver disease, characterized by inflammation of the liver with concurrent fat accumulation in liver. Mere deposition of fat in the liver is termed steatosis, and together these constitute fatty liver changes.There are two main types of fatty liver disease: alcohol-related fatty liver disease and non-alcoholic fatty liver disease (NAFLD). Risk factors for NAFLD include diabetes, obesity and metabolic syndrome. When inflammation is present it is referred to as alcoholic steatohepatitis and nonalcoholic steatohepatitis (NASH). Steatohepatitis of either cause may progress to cirrhosis, and NASH is now believed to be a frequent cause of unexplained cirrhosis (at least in Western societies). NASH is also associated with lysosomal acid lipase deficiency.The word is from steato-, meaning "fat" and hepatitis, meaning "inflammation of the liver".

Browse All Tags